证券代码：600104 证券简称：上汽集团 公告编号：临 2025－039 上海汽车集团股份有限公司 关于实施回购股份注销暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 上海汽车集团股份有限公司（以下简称"公司" ）将于 2025 年 （以 下简称"此次回购股份"）。本次注销完成后，公司股份总数将由 一、注销此次回购股份的决策程序及信息披露 为提升上市公司质量和投资价值，落实《上海汽车集团股份有限 公司 2025 年度估值提升计划》 ，以实际行动回报投资者，公司分别于 会议、2024 年年度股东大会，审议通过了《关于注销回购股份、减 少注册资本并相应修订 <公司章程> 的议案》，同意注销存放于公司回 购专用证券账户的 80,021,941 股股份，相应核减公司注册资本及股份 总数，相应修订《公司章程》中的相关条款，并授权公司经营管理层 具体办理相关手续。 公司已根据相关法律、法规的规定就注销此次回购股份事项履行 了通知债权人程序，于 2025 年 6 月 28 日在上海证券交易所网站 ww ...

Core Viewpoint - Zhongheng Group has successfully completed its share repurchase plan for 2025, demonstrating confidence in its future development and intrinsic value [1][2] Group 1: Share Repurchase Details - The company repurchased a total of 118 million shares, accounting for 3.56% of its total share capital, at an average price of 2.55 yuan per share, with a total expenditure of 301 million yuan [1] - The repurchase plan was initiated in February 2025, and all repurchased shares will be canceled to reduce registered capital, changing the total share capital from 3.313 billion shares to 3.195 billion shares [1] Group 2: Market Impact and Confidence - Market analysts view the share repurchase as a positive signal that effectively boosts market confidence, reflecting the company's judgment on the reasonableness of its current stock price and its commitment to optimizing capital structure for high-quality development [1][2] - Since the implementation of the repurchase plan, Zhongheng Group has consistently advanced its repurchase efforts, notably increasing its repurchase volume in April amid market volatility, acquiring approximately 42.15 million shares for 101 million yuan [2] Group 3: Historical Context and Future Strategy - This marks Zhongheng Group's third share repurchase after those in 2018 and 2024, with a total of 730 million yuan spent on repurchasing over 291 million shares in recent years [2] - The company has also emphasized shareholder rights protection through consistent cash dividends, with total dividends exceeding 3.5 billion yuan since its listing [2] - Looking ahead, Zhongheng Group aims to focus on a dual-driven strategy of industry and capital to ensure that its investment value reflects its quality and supports high-quality development [2]

Group 1 - The company completed the cancellation of 48,178 shares, which accounted for 0.0089% of the total share capital before cancellation, resulting in a new total share capital of 542,910,913 shares [1][3] - The company had previously repurchased a total of 5,018,178 shares, representing 0.98% of the total share capital at that time, with a total expenditure of approximately 150.362 million yuan [1][2] - The shares repurchased were intended for an employee stock ownership plan, with a maximum participation price set at 13.51 yuan per share for up to 213 employees [2][3] Group 2 - The company has confirmed that the cancellation of repurchased shares complies with relevant laws and regulations and will not significantly impact its financial status or operational results [3][4] - Following the cancellation, the company will proceed with necessary business registration and filing as per legal requirements [5]

证券代码：688568.SH 证券简称：中科星图 公告编号：2025-057 中科星图股份有限公司 关于完成回购股份注销暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购审批情况和回购方案内容 中科星图股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开第三届董事 会第四次会议、第三届监事会第四次会议，于 2025 年 5 月 7 日召开 2025 年第一次临时 股东大会，审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。公司拟使 用首次公开发行股票取得的超募资金和公司自有资金以集中竞价交易方式回购公司已 发行的人民币普通股（A 股）股票，本次回购的股份拟用于注销并减少公司注册资本， 本次回购的资金总额不低于人民币 4,000 万元（含）且不超过人民币 6,000 万元（含）， 回购价格不超过人民币 84.39 元/股（含），回购期限为自公司股东大会审议通过本次回 购方案之日起不超过 12 个月。具体内容详见公司分别于 2025 年 4 月 15 日、2025 年 5 月 8 日 ...

Core Viewpoint - The company has completed a share buyback and cancellation process, reducing its total share capital from 810 million shares to 808 million shares through the repurchase of 1.4767 million shares, which represents 0.1824% of the total shares before cancellation [1] Group 1 - As of August 20, 2025, the company repurchased a total of 1.4767 million shares through a dedicated securities account via centralized bidding [1] - The repurchased shares accounted for 0.1824% of the company's total share capital prior to cancellation, which was 810 million shares [1] - The cancellation of the repurchased shares was completed on August 22, 2025, with the total share capital adjusted to 808 million shares [1]

Core Viewpoint - The company has approved the cancellation of 112,750,413 repurchased shares, reducing its total share capital and registered capital, which will enhance earnings per share and shareholder returns without significantly impacting its financial status or operations [1][4]. Group 1: Share Repurchase Implementation - The company initiated a share repurchase plan on November 11, 2021, with a budget between RMB 800 million and RMB 1.5 billion, at a maximum price of RMB 6.50 per share, within a 12-month period [1][2]. - By November 10, 2022, the company had repurchased a total of 112,750,413 shares, accounting for approximately 4.51% of the total shares before cancellation, with a total transaction amount not specified [2][3]. Group 2: Reasons and Quantity for Cancellation - The shares were intended for employee stock incentive plans, but due to the expiration of the three-year period without implementation, the company decided to cancel these shares [2][3]. Group 3: Changes in Share Capital Structure - After the cancellation, the total number of shares will decrease from 2,500,783,182 to 2,388,032,769, with limited and unrestricted shares adjusted accordingly [3][4]. - The structure will reflect 74,950,521 shares with limited sale conditions (3.14%) and 2,313,082,248 unrestricted shares (96.86%) post-cancellation [3]. Group 4: Impact and Future Arrangements - The cancellation is expected to improve earnings per share and will not affect the company's financial condition or future development significantly [4]. - The company will apply for share cancellation procedures and make necessary amendments to its articles of association and business registration following shareholder approval [4].

Core Viewpoint - Shanghai Cambridge Technology Co., Ltd. has completed the registration of changes in its business license, reflecting a reduction in registered capital and adjustments to its governance structure following the implementation of a restricted stock incentive plan [1][2]. Group 1: Business Changes - The company held two extraordinary general meetings on November 30, 2022, and June 16, 2025, to approve the stock incentive plan and the reduction of registered capital [1]. - The total share capital has been reduced from 268,041,841 shares to 268,019,841 shares, and the registered capital has decreased from RMB 268,041,841 to RMB 268,019,841 [2]. Group 2: Shareholder Information - Cambridge Industries Company Limited, the controlling shareholder, held 36,556,453 shares (13.64% of total shares) before the changes, while Shanghai Kangling Technology Partnership held 5,918,476 shares (2.21%) [7]. - After the changes, the combined shareholding of the information disclosure obligors decreased from 15.85% to 15.00% of the total shares [8][10]. Group 3: Future Plans - The information disclosure obligors have no plans to increase their shareholding in the next 12 months [10]. - A reduction plan was disclosed on May 13, 2025, allowing for a maximum reduction of 8,041,254 shares (2.00% of total shares) within three months [11].

Group 1 - The company plans to change the purpose of repurchased A-shares from employee stock ownership plan to cancellation and reduction of registered capital, involving the cancellation of 67,786,990 shares [1] - After the cancellation, the company's total share capital is expected to be reduced, with specific details provided in the announcement dated August 19, 2025 [1] - The company is also proposing amendments to its Articles of Association in accordance with relevant laws and regulations due to changes in registered capital [2]

Group 1 - The company has changed the purpose of its share repurchase plan, now intending to use the repurchased shares for capital reduction instead of employee stock ownership plans [1] - A total of 6,379,004 shares will be canceled, leading to a corresponding reduction in the company's registered capital [2] - The final situation of the company's capital changes will be confirmed by the China Securities Depository and Clearing Corporation after the completion of the cancellation process [2] Group 2 - The company is notifying creditors about the capital reduction, allowing them to claim their debts within 45 days from the announcement [2] - Creditors must provide relevant documentation to assert their claims, including contracts and proof of debt relationships [3] - Specific requirements for both corporate and individual creditors are outlined for submitting claims [3]

Core Viewpoint - The company, Buchang Pharma, is demonstrating long-term confidence in its value by announcing the cancellation of repurchased shares, which reflects its commitment to shareholder returns and social responsibility [1][2]. Group 1: Share Repurchase and Cancellation - Buchang Pharma plans to cancel 51,474,203 repurchased shares, which accounts for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 to 1,054,568,442 shares [1]. - Since its listing, the company has conducted three share repurchases, totaling 87,012,200 shares and spending 1,744.43 million yuan, with 35,538,000 shares already canceled [2]. - The cancellation of shares is expected to enhance earnings per share and net asset value, stabilize stock prices, and reflect the company's financial health and cash flow [2]. Group 2: Financial Performance and Shareholder Returns - The company has approved a mid-term dividend plan for 2025, reinforcing its commitment to returning value to shareholders, with cumulative dividends exceeding 7.5 billion yuan since its establishment [2]. - Buchang Pharma has paid over 32 billion yuan in taxes and has contributed to local economic development through job creation [3]. Group 3: Industry Position and Product Development - With over 30 years in the traditional Chinese medicine sector, Buchang Pharma has developed a diversified portfolio across various pharmaceutical categories, becoming a leading innovator in traditional Chinese medicine [4]. - The company holds 468 valid patents and is advancing 213 research projects, focusing on major diseases and cultivating significant products [4]. - Recent international approvals for products like the "Stabilizing Heart Granules" in Malaysia and "Pulmonary Detox Granules" in Canada, Kazakhstan, and Uzbekistan indicate the company's global expansion efforts [5]. Group 4: Vision and Social Responsibility - Buchang Pharma aims to be "China's Johnson & Johnson, and the world's Buchang," emphasizing its commitment to social responsibility and innovation in the healthcare sector [5].